Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05727891 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Tonabersat for DME

A Phase 2 study of Diabetic Macular Edema, sponsored by Jaeb Center for Health Research.

Active
Registry status
Phase 2
Development phase
128
Enrollment target
20
Study locations

NCT05727891: Active Phase 2 study of Diabetic Macular Edema, sponsored by Jaeb Center for Health Research.

NCT05727891 is a Phase 2 study of Diabetic Macular Edema that is active but no longer recruiting, run by Jaeb Center for Health Research. The registered enrollment target is 128 participants, below the 3,792-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05727891, a Phase 2 study of Diabetic Macular Edema, is active but no longer recruiting, sponsored by Jaeb Center for Health Research.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
128 participants
Enrollment target
20
Study locations

Study Summary

This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG Tonabersat

Study Locations (20)

California

  • Retina Associates of Southern California - Huntington Beach
  • Loma Linda University - Loma Linda
  • East Bay Retina Consultants, Inc. - Oakland
  • Southern California Desert Retina Consultants, Inc. - Palm Desert
  • Macula Retina Vitreous Institute - Torrance

Florida

  • National Ophthalmic Research Institute - Fort Myers
  • University of Florida- Jacksonville - Jacksonville
  • Central Florida Retina Institute - Lakeland
  • Florida Retina Consultants - Lakeland
  • Southeast Eye Institute, P.A. dba Eye Associates of Pinellas - Pinellas Park

Georgia

  • Southeast Retina Center - Augusta
  • Thomas Eye Group - Sandy Springs

Massachusetts

  • Boston Medical Center Corporation - Boston
  • Joslin Diabetes Center - Boston

Illinois

  • Illinois Retina Associates - Oak Park

Indiana

  • Midwest Eye Institute - Indianapolis

Louisiana

  • Joseph E. Humble and Raymond Haik PTRS DBA Eye Assoc of Northeast Louisiana - West Monroe

Maryland

  • Elman Retina Group - Baltimore

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2023-05-02
Est. Completion 2026-01
Phase Phase 2
Jaeb Center for Health Research

119 total trials

What the registry record for NCT05727891 still lists

NCT05727891 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 3,792-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05727891 names 20 study sites across 10 states, led by California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT05727891 about?

NCT05727891 is a clinical study titled "Evaluation of Tonabersat for DME". This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.

What is the current status of trial NCT05727891?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2023-05-02. Estimated completion is 2026-01.

What conditions does trial NCT05727891 study?

This clinical trial studies the following conditions: Diabetic Macular Edema.

What interventions are being tested in trial NCT05727891?

The interventions under investigation include: Placebo (OTHER), Tonabersat (DRUG).

Who is sponsoring clinical trial NCT05727891?

This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05727891 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Macular Edema

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05727891's enrollment target sits among peer trials

128 29th of 63 higher than 35 of 63 other Diabetic Macular Edema trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02870738 · 128 participants · Phase 2

    Bladder Directed vs. Pelvic Floor Therapy in IC/BPS

  • NCT03294460 · 128 participants · Phase 1

    Nicotinic Receptor Genetic Variation and Alcohol Reward

  • NCT04149977 · 128 participants · NA

    Blood Flow Restriction Therapy in Lower Limb Extensor Injuries

  • NCT04373057 · 128 participants · Phase 1

    Prebiotic Galacto-oligosaccharide and Acute GVHD

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05727891, the US trial registry maintained by the National Library of Medicine. NCT05727891 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.